<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="editorial" dtd-version="1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-title-group>
<journal-title>Clinical and Experimental Pediatrics</journal-title><abbrev-journal-title>Clin Exp Pediatr</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2713-4148</issn>
<publisher>
<publisher-name>Korean Pediatric Society</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3345/cep.2020.00745</article-id>
<article-id pub-id-type="publisher-id">cep-2020-00745</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
<subj-group subj-group-type="heading">
<subject>Neonatology (Perinatology)</subject>
</subj-group></subj-group></article-categories>
<title-group>
<article-title>Fluconazole prophylaxis for prevention of invasive candidiasis in extremely preterm infants</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3888-334X</contrib-id>
<name><surname>Kim</surname><given-names>Chun Soo</given-names></name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="corresp" rid="c1-cep-2020-00745"/>
<xref ref-type="aff" rid="af1-cep-2020-00745"/>
</contrib>
<aff id="af1-cep-2020-00745">
Department of Pediatrics, Keimyung University School of Medicine, Daegu, <country>Korea</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-cep-2020-00745">Corresponding author: Chun Soo Kim, MD, PhD. Department of Pediatrics, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu 42601, Korea Email: <email>cskim@dsmc.or.kr</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>4</month>
<year>2021</year></pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>7</month>
<year>2020</year></pub-date>
<volume>64</volume>
<issue>4</issue>
<fpage>167</fpage>
<lpage>168</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>4</month>
<year>2020</year></date>
<date date-type="rev-recd">
<day>22</day>
<month>6</month>
<year>2020</year></date>
<date date-type="accepted">
<day>6</day>
<month>7</month>
<year>2020</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x000a9; 2021 by The Korean Pediatric Society</copyright-statement>
<copyright-year>2021</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions>
<related-article related-article-type="commentary-article" id="cep-2020-00745" elocation-id="cep.2019.01431"/>
</article-meta></front>
<body>
<p>After gram-positive and -negative bacteria, <italic>Candida</italic> sepsis is the third most common hospital-acquired infection in neonatal intensive care units (NICUs), accounting for about 12% of cases of late-onset sepsis in very low birth weight infants (VLBWI), weighing less than 1,500 g &#x0005b;<xref ref-type="bibr" rid="b1-cep-2020-00745">1</xref>&#x0005d;. The incidence of invasive candidiasis in extremely preterm infants varies among NICUs, reportedly affecting 3%&#x02013;23% of extremely low birth weight infants (ELBWI), weighing less than 1,000 g at birth and 0%&#x02013;6% of VLBWI &#x0005b;<xref ref-type="bibr" rid="b2-cep-2020-00745">2</xref>&#x0005d;.</p>
<p>In extremely preterm infants, invasive procedures, such as endotracheal intubation and central venous catheterization, broad-spectrum antibiotics, parenteral nutrition, and <italic>Candida</italic> colonization, including the gastrointestinal system, skin, and respiratory tract, are common risk factors for invasive infections &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;. Delayed treatment for candidemia may cause disseminated infection of the end organs, including meningoencephalitis, peritonitis, renal mycetoma, and endophthalmitis &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;. Extremely preterm infants with invasive candidiasis have a high mortality rate of about 30% despite various intensive treatments, including antifungal agents. Those that survive have a higher incidence of neurodevelopmental disorders in infancy than babies without infection &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;. Additionally, infection can lead to longer hospital stays and higher medical expenses &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;.</p>
<p>In a recent issue of <italic>Clinical and Experimental Pediatrics</italic>, Anaraki et al. &#x0005b;<xref ref-type="bibr" rid="b4-cep-2020-00745">4</xref>&#x0005d; published a systematic review and meta-analysis on fluconazole prophylaxis (FP) for preventing invasive candidiasis in preterm VLBWI and ELBWI. This article reviewed 16 clinical studies on FP in extremely preterm infants over the last 16 years and compared and summarized the birth weights of the target group, the dosage and dosing interval of the antifungal agent, and the duration of administration. Despite the heterogeneity of comparative variables among clinical trials, extremely preterm infants treated with FP showed lower rates of <italic>Candida</italic> colonization, invasive infection, and mortality than the control group.</p>
<p>Prior to the introduction of FP, common infection control measures should be established to reduce invasive <italic>Candida</italic> infection rates among NICU patients. Stewardship on medications, including broad-spectrum antibiotics, antacids, and steroids, and the development of feeding protocols may reduce the risk of <italic>Candida</italic> infection in preterm infants &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;. Additionally, standardized bundles for inserting and maintaining central lines help reduce central line&#x02013;associated bloodstream infections, including <italic>Candida</italic> sepsis &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;.</p>
<p>FP is primarily recommended for preterm infants with a birth weight of less than 1,000 g, or a gestational age of less than 28 weeks, in a NICU with a high incidence of invasive candidiasis, affecting more than 5%&#x02013;10% of all hospitalized patients &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;. Additionally, patients with bacterial bloodstream infections and gastrointestinal pathologies, including congenital anomalies (e.g., tracheoesophageal fistula, gastroschisis, omphalocele, and intestinal atresia), necrotizing enterocolitis, and spontaneous intestinal perforation, may be included in the target group for chemoprophylaxis &#x0005b;<xref ref-type="bibr" rid="b5-cep-2020-00745">5</xref>&#x0005d;. Fluconazole doses used for prophylaxis vary from 3&#x02013;4 mg/kg and up to 6 mg/kg, and the recommended doses have been applied differently among NICUs. According to recent meta-analysis data, when treating extremely preterm infants with FP, both 3 and 6 mg/kg doses were effective at reducing invasive candidiasis and infection-related mortality compared to controls, although an increased dose was not associated with higher efficacy &#x0005b;<xref ref-type="bibr" rid="b6-cep-2020-00745">6</xref>&#x0005d;. Therefore, considering the greater potential toxicity and higher cost of increased FP doses, it is better to use the lowest dose (3 mg/kg). Preterm infants (birth weight &lt;1,000 g or gestational age &lt;28 weeks) should receive the prophylaxis from birth until the 6th week of life, but treatment should be discontinued sooner if a baby achieves full enteral nutrition and intravenous access is otherwise unnecessary &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;. Infants with bacterial sepsis may be considered for prophylaxis during treatment with broad-spectrum antibiotics, including third- and fourth-generation cephalosporins, as well as carbapenems &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>,<xref ref-type="bibr" rid="b5-cep-2020-00745">5</xref>&#x0005d;. Infants with gastrointestinal diseases requiring long-term fasting or antibiotic treatment may be candidates for prophylaxis during the period when intravenous access is necessary &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>,<xref ref-type="bibr" rid="b5-cep-2020-00745">5</xref>&#x0005d;. When chemoprophylaxis is used in the NICU, countermeasures against the emergence of fluconazole-resistant species should be implemented (<xref rid="f1-cep-2020-00745" ref-type="fig">Fig. 1</xref>) &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>,<xref ref-type="bibr" rid="b7-cep-2020-00745">7</xref>&#x0005d;.</p>
<p>The safety of FP has been evaluated. Cholestasis, which often occurs in extremely preterm infants treated with FP, is associated with underlying diseases during hospitalization, such as total parenteral nutrition, bacterial infections, or necrotizing enterocolitis, and is not related to fluconazole dose or duration &#x0005b;<xref ref-type="bibr" rid="b3-cep-2020-00745">3</xref>&#x0005d;. Neurodevelopmental safety has been evaluated in ELBWI receiving chemoprophylaxis. Neurological evaluations performed at 18&#x02013;22 months and about 8&#x02013;10 years of age revealed no difference in the rate of neurodevelopmental impairment between the fluconazole and placebo groups &#x0005b;<xref ref-type="bibr" rid="b8-cep-2020-00745">8</xref>,<xref ref-type="bibr" rid="b9-cep-2020-00745">9</xref>&#x0005d;. Long-term follow-up data of more than 10 years indicated no emergence of native fluconazole-resistant species, including <italic>Candida glabrata</italic> and <italic>Candida krusei</italic>, after the introduction of FP in the NICU &#x0005b;<xref ref-type="bibr" rid="b7-cep-2020-00745">7</xref>,<xref ref-type="bibr" rid="b10-cep-2020-00745">10</xref>&#x0005d;.</p>
<p>In conclusion, FP effectively decreases <italic>Candida</italic> colonization, invasive infection, and mortality in extremely preterm infants. A schedule of lower doses and less frequent administrations of fluconazole for NICU patients is recommended. After the introduction of FP, monitoring the emergence of resistant <italic>Candida</italic> species and the susceptibility of fluconazole should continue.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict"><p>No potential conflicts of interest relevant to this article are reported.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="b1-cep-2020-00745">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Stoll</surname><given-names>BJ</given-names></name>
<name><surname>Hansen</surname><given-names>N</given-names></name>
<name><surname>Fanaroff</surname><given-names>AA</given-names></name>
<name><surname>Wright</surname><given-names>LL</given-names></name>
<name><surname>Carlo</surname><given-names>WA</given-names></name>
<name><surname>Ehrenkranz</surname><given-names>RA</given-names></name>
<etal/>
</person-group>
<article-title>Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network</article-title>
<source>Pediatrics</source>
<year>2002</year>
<volume>110</volume>
<fpage>285</fpage>
<lpage>91</lpage>
</element-citation></ref>
<ref id="b2-cep-2020-00745">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaufman</surname><given-names>DA</given-names></name>
</person-group>
<article-title>Epidemiology and prevention of neonatal candidiasis: fluconazole for all neonates?</article-title>
<source>Adv Exp Med Biol</source>
<year>2010</year>
<volume>659</volume>
<fpage>99</fpage>
<lpage>119</lpage>
</element-citation></ref>
<ref id="b3-cep-2020-00745">
<label>3</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Kaufman</surname><given-names>DA</given-names></name>
<name><surname>Manzoni</surname><given-names>P</given-names></name>
</person-group>
<chapter-title>Fungal and protozoal infections of the neonate</chapter-title>
<person-group person-group-type="editor">
<name><surname>Martin</surname><given-names>RJ</given-names></name>
<name><surname>Fanaroff</surname><given-names>AA</given-names></name>
<name><surname>Walsh</surname><given-names>MC</given-names></name>
</person-group>
<source>Fanaroff and Martin&#x02019;s neonatal-perinatal medicine</source>
<edition>11th ed</edition>
<publisher-loc>Philadelphia (PA)</publisher-loc>
<publisher-name>Elsevier</publisher-name>
<year>2020</year>
<fpage>809</fpage>
<lpage>43</lpage>
</element-citation></ref>
<ref id="b4-cep-2020-00745">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Anaraki</surname><given-names>MR</given-names></name>
<name><surname>Nouri-Vaskeh</surname><given-names>M</given-names></name>
<name><surname>Oskoei</surname><given-names>SA</given-names></name>
</person-group>
<article-title>Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis</article-title>
<source>Clin Exp Pediatr</source>
<year>2020</year>
<month>May</month>
<day>14</day>
<comment>[Epub]. <ext-link xlink:href="https://doi.org/10.3345/cep.2019.01431" ext-link-type="uri">https://doi.org/10.3345/cep.2019.01431</ext-link></comment>
</element-citation></ref>
<ref id="b5-cep-2020-00745">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Feja</surname><given-names>KN</given-names></name>
<name><surname>Wu</surname><given-names>F</given-names></name>
<name><surname>Roberts</surname><given-names>K</given-names></name>
<name><surname>Loughrey</surname><given-names>M</given-names></name>
<name><surname>Nesin</surname><given-names>M</given-names></name>
<name><surname>Larson</surname><given-names>E</given-names></name>
<etal/>
</person-group>
<article-title>Risk factors for candidemia in critically ill infants: a matched case-control study</article-title>
<source>J Pediatr</source>
<year>2005</year>
<volume>147</volume>
<fpage>156</fpage>
<lpage>61</lpage>
</element-citation></ref>
<ref id="b6-cep-2020-00745">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Leonart</surname><given-names>LP</given-names></name>
<name><surname>Tonin</surname><given-names>FS</given-names></name>
<name><surname>Ferreira</surname><given-names>VL</given-names></name>
<name><surname>Tavares da Silva Penteado</surname><given-names>S</given-names></name>
<name><surname>de Ara&#x000fa;jo Motta</surname><given-names>F</given-names></name>
<name><surname>Pontarolo</surname><given-names>R</given-names></name>
</person-group>
<article-title>Fluconazole doses used for prophylaxis of invasive fungal infection in neonatal intensive care units: a network meta-analysis</article-title>
<source>J Pediatr</source>
<year>2017</year>
<volume>185</volume>
<fpage>129</fpage>
<lpage>35</lpage>
</element-citation></ref>
<ref id="b7-cep-2020-00745">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Manzoni</surname><given-names>P</given-names></name>
<name><surname>Leonessa</surname><given-names>M</given-names></name>
<name><surname>Galletto</surname><given-names>P</given-names></name>
<name><surname>Latino</surname><given-names>MA</given-names></name>
<name><surname>Arisio</surname><given-names>R</given-names></name>
<name><surname>Maule</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies</article-title>
<source>Pediatr Infect Dis J</source>
<year>2008</year>
<volume>27</volume>
<fpage>731</fpage>
<lpage>7</lpage>
</element-citation></ref>
<ref id="b8-cep-2020-00745">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamin</surname><given-names>DK</given-names><suffix>Jr</suffix></name>
<name><surname>Hudak</surname><given-names>ML</given-names></name>
<name><surname>Duara</surname><given-names>S</given-names></name>
<name><surname>Randolph</surname><given-names>DA</given-names></name>
<name><surname>Bidegain</surname><given-names>M</given-names></name>
<name><surname>Mundakel</surname><given-names>GT</given-names></name>
<etal/>
</person-group>
<article-title>Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial</article-title>
<source>JAMA</source>
<year>2014</year>
<volume>311</volume>
<fpage>1742</fpage>
<lpage>9</lpage>
</element-citation></ref>
<ref id="b9-cep-2020-00745">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaufman</surname><given-names>DA</given-names></name>
<name><surname>Cuff</surname><given-names>AL</given-names></name>
<name><surname>Wamstad</surname><given-names>JB</given-names></name>
<name><surname>Boyle</surname><given-names>R</given-names></name>
<name><surname>Gurka</surname><given-names>MJ</given-names></name>
<name><surname>Grossman</surname><given-names>LB</given-names></name>
<etal/>
</person-group>
<article-title>Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age</article-title>
<source>J Pediatr</source>
<year>2011</year>
<volume>158</volume>
<fpage>759</fpage>
<lpage>65</lpage>
</element-citation></ref>
<ref id="b10-cep-2020-00745">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Luparia</surname><given-names>M</given-names></name>
<name><surname>Landi</surname><given-names>F</given-names></name>
<name><surname>Mesini</surname><given-names>A</given-names></name>
<name><surname>Militello</surname><given-names>MA</given-names></name>
<name><surname>Galletto</surname><given-names>P</given-names></name>
<name><surname>Farina</surname><given-names>D</given-names></name>
<etal/>
</person-group>
<article-title>Fungal ecology in a tertiary neonatal intensive care unit after 16 years of routine fluconazole prophylaxis: no emergence of native fluconazole-resistant strains</article-title>
<source>Am J Perinatol</source>
<year>2019</year>
<volume>36</volume>
<fpage>S126</fpage>
<lpage>33</lpage>
</element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figure</title>
<fig id="f1-cep-2020-00745" position="float">
<label>Fig. 1.</label><caption><p>A possible guideline for fluconazole prophylaxis in extremely preterm infants. ELBWI, extremely low birth weight infants; MIC, minimum inhibitory concentration; NPO, nil per os.</p></caption>
<graphic xlink:href="cep-2020-00745f1.tif"/></fig>
</sec>
</back></article>